Otonomy names new CMO
This article was originally published in Scrip
Executive Summary
Otonomy, a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for disorders of the inner and middle ear, has named Dr Dean Hakanson chief medical officer. Dr Hakanson has more than 16 years of industry experience in medical affairs, market access and health economic research with pharmaceutical companies including Novartis, Bristol-Myers Squibb, Genentech and GlaxoSmithKline. He joins Otonomy from Novartis, where he was most recently vice-president and head of health economics and outcomes research (HE&OR) for US medical and drug regulatory affairs.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.